JPMorgan Downgrades Rapt Therapeutics (RAPT) to Underweight
JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (NASDAQ: RAPT) from Neutral to Underweight.The analyst comments "We are downgrading RAPT (RAPT) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)